NextFin News - The U.S. Food and Drug Administration (FDA) moved on Thursday to shut down the primary legal loophole that has allowed a multibillion-dollar market for "copycat" weight-loss injections to flourish. In a major regulatory victory for Novo Nordisk and Eli Lilly, the agency proposed excluding the active ingredients in Wegovy, Ozempic, Zepbound, and Mounjaro from the list of substances that outsourcing facilities can use for bulk compounding.
The proposal, announced by FDA Commissioner Marty Makary, targets semaglutide and tirzepatide—the blockbuster molecules that have transformed the pharmaceutical landscape. Under federal law, 503B outsourcing facilities are permitted to manufacture compounded versions of drugs only when there is a "clinical need" or when the branded versions are in short supply. The FDA’s new stance is unequivocal: with manufacturing capacity finally catching up to demand, the agency finds "no clinical need" for these facilities to continue mass-producing these treatments from bulk substances.
The market reaction was immediate and decisive. Shares of Novo Nordisk surged 5.83% to trade at approximately $39.14, while Eli Lilly climbed 8.19% to $976.76. These gains reflect investor relief that the "wild west" of compounded GLP-1s—which analysts estimate has captured a significant slice of the obesity market—is nearing an end. For years, patients unable to find or afford branded pens turned to compounding pharmacies for cheaper, often unbranded vials of the medication.
U.S. President Trump has previously pressured pharmaceutical giants to lower costs, and both companies have responded by investing billions into new factories and striking "most favored nation" pricing deals. This regulatory shift suggests the administration is now pivoting toward protecting the intellectual property of those who have complied with supply demands. By removing these ingredients from the 503B bulk list, the FDA is effectively telling the industry that the "shortage era" justification for mass compounding is over.
However, the proposal does not represent a total ban. It specifically targets 503B outsourcing facilities, which produce drugs in large batches. Smaller 503A pharmacies, which mix medications for individual patients based on specific prescriptions, remain under the jurisdiction of state boards and are not directly affected by this specific bulk-list exclusion. This distinction ensures that patients with legitimate medical reasons for a customized formulation—such as an allergy to an inactive ingredient in the branded version—still have options.
The move has drawn sharp criticism from the compounding industry. Advocates for these pharmacies argue that compounded versions provide essential price competition in a market where branded GLP-1s can still cost hundreds of dollars per month. They contend that the FDA’s definition of "available" ignores the reality of many patients whose insurance does not cover weight-loss drugs, leaving them with no affordable alternative if compounding is restricted.
The FDA will accept public comments on the proposal until late June. If finalized, the ruling will force a massive consolidation in the weight-loss market, shifting millions of users back toward the branded ecosystem. For Novo Nordisk and Eli Lilly, the challenge now shifts from defending their patents to ensuring their supply chains can handle the influx of patients who will no longer have access to their cheaper, compounded counterparts.
Explore more exclusive insights at nextfin.ai.
